#Italy #Implantica #RefluxStop™ #GERD #Brunico

Implantica Expands RefluxStop™ Centers in Italy

Implantica AG, a notable player in the medtech arena, is making significant strides in enhancing access to advanced treatments for gastroesophageal reflux disease (GERD) in Italy. Recently, the company marked the opening of its ninth RefluxStop™ Center of Excellence at Ospedale di Brunico, under the expert care of Dr. Günther Sitzmann. This center stands at the forefront of innovation, offering a groundbreaking solution for the estimated 11 million people suffering from GERD in Italy.

In December 2024, Dr. Sitzmann successfully completed the first RefluxStop™ procedures, marking a new chapter in surgical interventions for this widespread condition. Collaborating with Prof. Dr. Moustafa Elshafei from Nordwest Hospital in Frankfurt, Dr. Sitzmann performed surgeries on two patients, both of whom showed remarkable recovery. Building on this success, the team has already scheduled further procedures for January 2025.

Dr. Sitzmann expressed optimism about the potential of RefluxStop™, stating, "It’s exciting to be at the start of a revolution in the surgical treatment of GERD. With RefluxStop™, I can offer the benefits of a durable solution to many chronic GERD patients looking for an innovative way to reduce side effects and significantly improve their quality of life."

The RefluxStop™ procedure addresses the underlying cause of GERD by restoring the natural anatomy and physiology of the lower esophageal sphincter without the complications typically associated with traditional surgeries. Unlike conventional methodologies that encircle the food passageway—which often lead to difficulties in swallowing and other complications—RefluxStop™ maintains the body’s original structures. This innovative device reconstructs the crucial components of the anti-reflux barrier, thereby enabling many patients who previously may not have been candidates for surgical interventions to seek this treatment.

Dr. Peter Forsell, CEO and inventor of RefluxStop™, highlighted the significance of this development for the healthcare landscape in Italy, emphasizing, "We're proud to partner with Dr. Sitzmann of the esteemed Ospedale di Brunico as he seeks the most advanced treatments for GERD patients. The financial burden of GERD on the healthcare system is immense, and innovations like RefluxStop™ have the power to drive transformative change for patients."

Currently, there are plans for additional RefluxStop™ centers to commence operations in the near future, responding to the growing demand for treatments that address GERD. With over 1,000 patients already treated across Europe using this method, the optimism surrounding its efficacy is palpable. Medical professionals are increasingly recognizing the value of this advanced technology in improving patient outcomes.

As the number of RefluxStop™ Centers continues to grow, Implantica's commitment to bringing advanced medical technology into routine practice underscores their mission to enhance patients’ lives, alleviate the burdens of chronic illness, and revolutionize surgical procedures for GERD treatment.

For more insights and updates on further developments from Implantica, keep an eye on innovative treatments shaping the future of gastroenterology.

For additional information, you may contact:

• - Nicole Pehrsson

Chief Corporate Affairs Officer
[Email Contact]
(CH) +41 (0)79 335 09 49

About Implantica: Implantica is dedicated to advancing healthcare with innovative technologies. Their flagship product, RefluxStop™, is a groundbreaking solution for GERD, supported by encouraging clinical trial results. With a robust pipeline of eHealth technology aiming to monitor health parameters remotely, Implantica remains a pioneering force in the medtech landscape. For full insights, visit Implantica's website.